What is Germitec?
Germitec operates at the intersection of medical technology and patient safety, specializing in the development of automated UV-C high-level disinfection systems. The company addresses the persistent challenge of healthcare-associated infections by providing fast, safe, and chemical-free solutions for ultrasound probes. Its core product portfolio, which includes the Chronos, Antigermix, and Yuvee technologies, is engineered to streamline clinical workflows while maintaining the highest levels of hygiene. By replacing traditional, labor-intensive disinfection methods with one-button, automated processes, Germitec effectively reduces the risk of cross-contamination, thereby enhancing the overall quality of care in hospitals and diagnostic centers worldwide.
How much funding has Germitec raised?
Germitec has raised a total of $30M across 1 funding round:
Other Financing Round
$30M
Other Financing Round (2025): $30M with participation from Eurazeo
Key Investors in Germitec
Eurazeo
Eurazeo is a leading global investment firm based in Paris, specializing in private equity, venture capital, and private debt to support transformational growth across diverse sectors.
What's next for Germitec?
With this major enterprise-level funding, Germitec is poised to scale its operations and deepen its penetration into international markets. The strategic roadmap likely involves increasing manufacturing capacity to meet the rising demand for its UV-C disinfection systems and investing in further research and development to refine its existing technology stack. As healthcare providers continue to prioritize infection control, Germitec is strategically positioned to lead the transition toward sustainable, automated disinfection practices. The company will likely focus on strengthening its commercial partnerships and expanding its footprint in key clinical segments, ensuring that its innovative solutions remain at the forefront of medical hygiene technology.
See full Germitec company page
